Azitra Inc. has announced promising safety data from its Phase 1b trial of ATR12-351, a live biotherapeutic candidate targeting Netherton syndrome. The trial, which is 50% enrolled, involves six patients who have received ATR12-351. The drug has been generally safe and well-tolerated, with only mild to moderate symptoms observed at the application site. The trial remains blinded, and no severe adverse events have been reported. Azitra is scheduled to present further details on this trial, along with its Phase 1/2 trial for ATR04-484, at the BIO International Convention in Boston on June 17, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY11944) on June 17, 2025, and is solely responsible for the information contained therein.